Drugs / Leuproreline
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05352178 | Apr 2022 → Apr 2027 expected | metastatic malignant neoplasm, metastatic prostate carcinoma | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02288130 Comparator | Dec 2014 → Jul 2017 | leiomyoma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | leuproreline | “Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or...” NCT05352178 ↗1“or (comparison) 11.25 mg Leuproreline injections at the onset of pretreatment with placebo tablets (once daily) .” NCT02288130 ↗ |
| Route | Subcutaneous | “leuproreline 7.5 mg sc” NCT05352178 ↗ |